Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Unknown 2Recruiting 1Completed 1

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 4

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Lymphoma, B-Cell 19Lymphoma, Large B-Cell, Diffuse 18Recurrence 13Lymphoma, Non-Hodgkin 13Multiple Myeloma 12Burkitt Lymphoma 11Lymphoma, Mantle-Cell 8Lymphoma 8Leukemia, Myeloid, Acute 8Carcinoma, Hepatocellular 7Pancreatic Neoplasms 6Neoplasms 6Lymphoma, Follicular 6Leukemia, Lymphocytic, Chronic, B-Cell 6Leukemia 5Glioma 5Colorectal Neoplasms 5Stomach Neoplasms 4Leukemia, B-Cell 4Hematologic Neoplasms 4Neoplasm, Residual 3Nasopharyngeal Carcinoma 3Melanoma 3Esophageal Neoplasms 3Breast Neoplasms 3Simpson-Golabi-Behmel syndrome 2Sarcoma, Synovial 2Sarcoma, Ewing 2Rhabdomyosarcoma 2

Interventions

Cyclophosphamide 18ofatumumab 14fludarabine 12Rituximab 11ibrutinib 10fludarabine phosphate 9acalabrutinib 7obinutuzumab 6Lenalidomide 6Bendamustine Hydrochloride 6venetoclax 5pirtobrutinib 4Vincristine 4Mesna 4Melphalan 4Immunotherapy, Adoptive 4Whole-Body Irradiation 3Mycophenolic Acid 3Chlorambucil 3Bortezomib 3Alemtuzumab 3spebrutinib 2navitoclax 2idelalisib 2Tacrolimus 2Tablets 2Stem Cell Transplantation 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2KW-2478 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Leukemia, B-Cell × Immunotherapy, Adoptive × Clear all
NCT06355739 2024-04-09

CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Institute of Hematology & Blood Diseases Hospital, China

Phase NA Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03068416 2021-10-20

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy

Uppsala University

Phase 2 Completed
24 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

NCT03598179 2019-08-07

XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
10 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

NCT03881774 2019-03-21

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

Henan Cancer Hospital

Phase 1 Unknown
20 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡